JP2003501345A - 勃起不全の治療における血管内皮成長因子の使用 - Google Patents

勃起不全の治療における血管内皮成長因子の使用

Info

Publication number
JP2003501345A
JP2003501345A JP2000594482A JP2000594482A JP2003501345A JP 2003501345 A JP2003501345 A JP 2003501345A JP 2000594482 A JP2000594482 A JP 2000594482A JP 2000594482 A JP2000594482 A JP 2000594482A JP 2003501345 A JP2003501345 A JP 2003501345A
Authority
JP
Japan
Prior art keywords
vegf
patient
penis
growth factor
vascular endothelial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000594482A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003501345A5 (enExample
Inventor
シャブサイ、リドワン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University
Original Assignee
Columbia University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University filed Critical Columbia University
Publication of JP2003501345A publication Critical patent/JP2003501345A/ja
Publication of JP2003501345A5 publication Critical patent/JP2003501345A5/ja
Pending legal-status Critical Current

Links

Classifications

    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27—FURNACES; KILNS; OVENS; RETORTS
    • F27D—DETAILS OR ACCESSORIES OF FURNACES, KILNS, OVENS OR RETORTS, IN SO FAR AS THEY ARE OF KINDS OCCURRING IN MORE THAN ONE KIND OF FURNACE
    • F27D27/00—Stirring devices for molten material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Mechanical Engineering (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2000594482A 1999-01-21 2000-01-21 勃起不全の治療における血管内皮成長因子の使用 Pending JP2003501345A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/234,591 US6706682B2 (en) 1999-01-21 1999-01-21 Uses of vascular endothelial growth factor in the treatment of erectile dysfunction
US09/234,591 1999-01-21
PCT/US2000/001535 WO2000043029A1 (en) 1999-01-21 2000-01-21 Uses of vascular endothelial growth factor in the treatment of erectile dysfunction

Publications (2)

Publication Number Publication Date
JP2003501345A true JP2003501345A (ja) 2003-01-14
JP2003501345A5 JP2003501345A5 (enExample) 2007-03-08

Family

ID=22882011

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000594482A Pending JP2003501345A (ja) 1999-01-21 2000-01-21 勃起不全の治療における血管内皮成長因子の使用

Country Status (9)

Country Link
US (2) US6706682B2 (enExample)
EP (1) EP1150698B1 (enExample)
JP (1) JP2003501345A (enExample)
AT (1) ATE303818T1 (enExample)
AU (1) AU2623700A (enExample)
CA (1) CA2360058A1 (enExample)
DE (1) DE60022478T2 (enExample)
DK (1) DK1150698T3 (enExample)
WO (1) WO2000043029A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706682B2 (en) * 1999-01-21 2004-03-16 The Trustees Of Columbia University In The City Of New York Uses of vascular endothelial growth factor in the treatment of erectile dysfunction
EP1223957A4 (en) * 1999-10-01 2003-05-14 Univ Duke A method of treating erectile dysfunction
US20020032153A1 (en) * 2000-03-10 2002-03-14 Whitehouse Martha Jo Methods and compositions for the treatment and prevention of erectile dysfunction
US6852323B2 (en) 2000-07-21 2005-02-08 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US7223406B2 (en) 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US8273063B2 (en) * 2006-05-30 2012-09-25 Yossi Gross Implantable pump for drug delivery to treat erectile dysfunction
US8152711B2 (en) * 2007-03-21 2012-04-10 Yossi Gross Implantable peristaltic pump to treat erectile dysfunction
US7818062B2 (en) * 2008-01-31 2010-10-19 Ed Tech Medical Ltd. Peristaltic pump for treatment of erectile dysfunction
US20120183519A1 (en) * 2011-01-13 2012-07-19 Biomet Biologics, Llc Treatment of erectile dysfunction using platelet-rich plasma
EP3242605A4 (en) 2015-01-06 2018-08-29 CardioVascular BioTherapeutics, Inc. Angiogenic treatment of ischemic heart disease
CA2976675A1 (en) * 2015-02-16 2016-08-25 Cardiovascular Biotherapeutics, Inc. Therapeutic angiogenesis for treating erectile conditions
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014748A1 (en) * 1994-11-10 1996-05-23 Nirec, Inc. AMELIORATION OF HUMAN ERECTILE DYSFUNCTION BY TREATMENT WITH iNOS, AND RELATED NOS AGENTS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236904A (en) 1989-09-18 1993-08-17 Senetek, Plc Erection-inducing methods and compositions
US5652225A (en) * 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
DE69939956D1 (de) 1998-05-01 2009-01-02 Univ Pittsburgh Verwendung von Myoblasten zur Herstellung eines Medikaments zur Behandlung der stressbedingten Harninkontinenz
JP3586194B2 (ja) 1998-05-15 2004-11-10 グラクソ グループ リミテッド 赤外サーモグラフィー
US6706682B2 (en) * 1999-01-21 2004-03-16 The Trustees Of Columbia University In The City Of New York Uses of vascular endothelial growth factor in the treatment of erectile dysfunction
EP1223957A4 (en) 1999-10-01 2003-05-14 Univ Duke A method of treating erectile dysfunction

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014748A1 (en) * 1994-11-10 1996-05-23 Nirec, Inc. AMELIORATION OF HUMAN ERECTILE DYSFUNCTION BY TREATMENT WITH iNOS, AND RELATED NOS AGENTS

Also Published As

Publication number Publication date
US20040048800A1 (en) 2004-03-11
US6706682B2 (en) 2004-03-16
AU2623700A (en) 2000-08-07
CA2360058A1 (en) 2000-07-27
WO2000043029A1 (en) 2000-07-27
US20030124094A1 (en) 2003-07-03
DE60022478T2 (de) 2006-06-22
DE60022478D1 (de) 2005-10-13
EP1150698A4 (en) 2003-01-29
EP1150698B1 (en) 2005-09-07
ATE303818T1 (de) 2005-09-15
EP1150698A1 (en) 2001-11-07
DK1150698T3 (da) 2006-01-16

Similar Documents

Publication Publication Date Title
Finch et al. Pattern of keratinocyte growth factor and keratinocyte growth factor receptor expression during mouse fetal development suggests a role in mediating morphogenetic mesenchymal‐epithelial interactions
Hemmati‐Brivanlou et al. Ventral mesodermal patterning in Xenopus embryos: expression patterns and activities of BMP‐2 and BMP‐4
Tuuri et al. The tissue distribution of activin beta A-and beta B-subunit and follistatin messenger ribonucleic acids suggests multiple sites of action for the activin-follistatin system during human development
Kojima et al. Expression of leukemia inhibitory factor in human endometrium and placenta
Dohrmann et al. Expression of activin mRNA during early development in Xenopus laevis
Laping et al. Transforming growth factor-β1 induces neuronal and astrocyte genes: tubulin α1, glial fibrillary acidic protein and clusterin
Tirone et al. Early gene regulation by nerve growth factor in PC12 cells: induction of an interferon-related gene.
Suzuki et al. Localization of HstI transcripts to the apical ectodermal ridge in the mouse embryo
Keshet et al. Proenkephalin A is expressed in mesodermal lineages during organogenesis.
JP2006521111A5 (enExample)
JPH11509088A (ja) 血管内皮増殖因子受容体をコードする遺伝子の転写調節
Liang et al. Activation of the complete mouse metallothionein gene locus in the maternal deciduum
Masson et al. Tumor necrosis factor receptor associated factor 4 (TRAF4) expression pattern during mouse development
Tatsumi et al. Induction of tryptophan 2, 3-dioxygenase in the mouse endometrium during implantation
BG63332B1 (bg) Метод за промяна на една или повече характеристики на клетки на репродуктивния тракт на бозайник
JP2002505841A (ja) 低酸素調節性遺伝子
Johnson et al. Expression of epidermal growth factor family gene members in early mouse development
JP2002525081A (ja) 低酸素により調節される遺伝子転写に特徴的な配列
DE60022478T2 (de) Verwendung des vaskularen endothelialen wachstumsfaktors zur behandlung von erektilen dysfunktionen
JP4565112B2 (ja) 毛髪成長促進剤、発毛促進剤及び脱毛症治療剤
US6362318B1 (en) Protein called EPIL/placentin, process for the preparation of this protein and pharmaceutical composition containing such, DNA coding for said protein
David et al. Quantitation of the mRNA levels of Epo and EpoR in various tissues in the ovine fetus
JP2002537776A (ja) 早発性卵巣機能不全の診断及び治療
CN101935673B (zh) 用于抑制小鼠γ-氨基丁酸转运蛋白亚型1的siRNA
JP4723133B2 (ja) 新規ヒトｂｍｃｃ１遺伝子

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100316

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100810